ClariTrial | Search Clinical Trials

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

36 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Phase 2Common Variable Immunodeficiency (CVID)Primary Immune Regulatory DisorderImmune Dysregulation

Hematopoietic stem cell transplant (HSCT)

Paul Szabolcs25 participants1 site · United StatesCompletes May 2030

Compare CT.gov Full analysis →

Recruiting

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata

Ruxolitinib

National Institute of Allergy and Infectious Diseases (NIAID)70 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Phase 3Rheumatoid Arthritis

MethotrexateAbataceptAdalimumab+13 more

University of Nebraska400 participants1 site · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Phase 2Phase 3Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus

LitifilimabPlacebo

Biogen450 participants314 sites · United States, Argentina, BelgiumCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Phase 3Oligoarthritis, JuvenilePolyarthritis, Juvenile, Rheumatoid Factor Negative

EtanerceptMethotrexateIntra-articular corticosteroid injections

Istituto Giannina Gaslini260 participants1 site · ItalyCompletes Feb 2025

Compare CT.gov Full analysis →

Recruiting

Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis

Emapalumab

National Institute of Allergy and Infectious Diseases (NIAID)10 participants1 site · United StatesCompletes Mar 2031

Compare CT.gov Full analysis →

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Phase 3Psoriatic Arthritis

ZasocitinibActive ComparatorPlacebo

Takeda1,088 participants189 sites · United States, Belgium, BulgariaCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Phase 2Primary Immunodeficiency (PID)Congenital Bone Marrow Failure SyndromesInherited Metabolic Disorders (IMD)

HydroxyureaAlemtuzumabFludarabine+2 more

Paul Szabolcs100 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Phase 2Glomerulonephritis Rapidly Progressive

ALE.F02RituximabGlucoCorticoid+3 more

Alentis Therapeutics AG80 participants49 sites · Czechia, Denmark, FranceCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Phase 2Systemic Lupus Erythematosus

BI 3000202Placebo

Boehringer Ingelheim405 participants134 sites · United States, Argentina, AustraliaCompletes Feb 2029

Compare CT.gov Full analysis →

Recruiting

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

Phase 3Lupus Nephritis

Voclosporin（QL1074）Placebo

Qilu Pharmaceutical Co., Ltd.270 participants10 sites · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Phase 2Systemic Lupus ErythematosusInflammatory MyopathySystemic Sclerosis (SSc)

BCMA-CD19 CAR-T therapy

Peking University People's Hospital50 participants1 site · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

Phase 1Phase 2Relapsing Polychondritis

Upadacitinibcorticosteroids and immunosuppressants

Peking University People's Hospital30 participants1 site · ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

1–15 of 36

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

36 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Phase 2Common Variable Immunodeficiency (CVID)Primary Immune Regulatory DisorderImmune Dysregulation

Hematopoietic stem cell transplant (HSCT)

Paul Szabolcs25 participants1 site · United StatesCompletes May 2030

Compare CT.gov Full analysis →

Recruiting

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata

Ruxolitinib

National Institute of Allergy and Infectious Diseases (NIAID)70 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Phase 3Rheumatoid Arthritis

MethotrexateAbataceptAdalimumab+13 more

University of Nebraska400 participants1 site · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Phase 2Phase 3Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus

LitifilimabPlacebo

Biogen450 participants314 sites · United States, Argentina, BelgiumCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Phase 3Oligoarthritis, JuvenilePolyarthritis, Juvenile, Rheumatoid Factor Negative

EtanerceptMethotrexateIntra-articular corticosteroid injections

Istituto Giannina Gaslini260 participants1 site · ItalyCompletes Feb 2025

Compare CT.gov Full analysis →

Recruiting

Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis

Emapalumab

National Institute of Allergy and Infectious Diseases (NIAID)10 participants1 site · United StatesCompletes Mar 2031

Compare CT.gov Full analysis →

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Phase 3Psoriatic Arthritis

ZasocitinibActive ComparatorPlacebo

Takeda1,088 participants189 sites · United States, Belgium, BulgariaCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Phase 2Primary Immunodeficiency (PID)Congenital Bone Marrow Failure SyndromesInherited Metabolic Disorders (IMD)

HydroxyureaAlemtuzumabFludarabine+2 more

Paul Szabolcs100 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Phase 2Glomerulonephritis Rapidly Progressive

ALE.F02RituximabGlucoCorticoid+3 more

Alentis Therapeutics AG80 participants49 sites · Czechia, Denmark, FranceCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Phase 2Systemic Lupus Erythematosus

BI 3000202Placebo

Boehringer Ingelheim405 participants134 sites · United States, Argentina, AustraliaCompletes Feb 2029

Compare CT.gov Full analysis →

Recruiting

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

Phase 3Lupus Nephritis

Voclosporin（QL1074）Placebo

Qilu Pharmaceutical Co., Ltd.270 participants10 sites · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Phase 2Systemic Lupus ErythematosusInflammatory MyopathySystemic Sclerosis (SSc)

BCMA-CD19 CAR-T therapy

Peking University People's Hospital50 participants1 site · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

Phase 1Phase 2Relapsing Polychondritis

Upadacitinibcorticosteroids and immunosuppressants

Peking University People's Hospital30 participants1 site · ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

1–15 of 36